Oligonucleotides Market Intelligence

Oligonucleotides Market Description

The global oligonucleotides CMO market is expected to grow at approximately 25 percent to reach a value of $ 550 million by 2020. Major oligonucleotides API manufacturers are concentrated in developed markets such as the U.S., Germany, and Belgium. Small players such as ST Pharm, GeneDesign, etc. from the developing region such as Asia are also gaining traction. Antisense oligonucleotides is a major type of oligonucleotides and 83 out of 142 ongoing clinical trials are based on it. Moreover, 70 percent of antisense oligonucleotides are being developed for the treatment of cancer. Apart from this, it is also being used in the treatment of other diseases such as HIV, rheumatoid arthritis, etc.

The report analyses the supply-demand chain and indicates that the demand for the oligonucleotides API market is growing at nearly 20-30% annually, which could further expand when these drugs are commercialized. The report covers the Porter’s Five Forces Analysis, which suggests that since oligonucleotides have more feasible commercial scale up than biologics, the threat of substitutes is low in the market. It gives a comprehensive overview of the major suppliers, market share, and industry best practices.

Beroe gathers intelligence through primary sources that include industry experts, researchers, and consultants, as well as current suppliers, producers and distributors. Secondary sources can include business journals, newsletters, magazines, market research data, company sources, and industry associations. Following data collation, analysis, and strategic review, the Final Research Report is published on Beroe LiVE.

Report Coverage

Major Suppliers and Market share
Supplier Profiling
Industry Best Practices
Porter’s Analysis – Oligonucleotide API

Oligonucleotides Market Trend, Analysis & Forecast

Category Intelligence on Oligonucleotides covers the following

Information relating to market, supply, cost, and pricing analysis
Hard to find data on cost and TCO models, supplier details, and performance benchmarks
Macroeconomic and regional trends impacting cost, supply, and other market dynamics
Category-specific negotiation and sourcing advice

icon
Executive Summary

icon
Market Analysis

icon
Supply Analysis

icon
Cost & Pricing Analysis

icon
Best Practices

Oligonucleotides Executive Summary
Oligonucleotides Global Market Analysis
Oligonucleotides Industry Analysis
Oligonucleotides Supplier Analaysis
Oligonucleotides Industry Best Practices

Global Market Overview on Oligonucleotides

More than 100 Oligonucleotides are currently under clinical trials and are moving towards regulatory approval. As they reach the market, demand for manufacturing capacity will increase forcing CMOs to expand .Global oligonucleotide CMO market is expected to grow at about 25 percent and reach a value of $550 million by 2020.

Supply Demand

Antisense oligonucleotides account for the major type of oligonucleotide currently in clinical trials. 83 out of the 142 ongoing clinical trials are antisense oligonucleotides.Currently there are 4-5 major CMOs in the market and they may not be able to support the growing demand once all drugs lined up for regulatory approval get market authorization

Oligonucleotides are regarded as the next big group of therapeutics after small molecule and biologics. This is mainly due to their promise of low drug development cost and ability to reach targets that conventional small molecule drugs cannot achieve
Antisense oligonucleotide therapeutics are currently the most promising class of oligonucleotides that have seen more success within the category
Challenges currently faced by oligonucleotide therapeutics include regulatory complexity, effective delivery of oligonucleotides, etc.
Although the number of oligo drugs in pipeline may be small as compared to small molecule and biologics, they still offer huge market potential

Market Overview – Supply Demand

Oligonucleotide API market has seen the demand accelerate and the market is growing at about 20-30% a year and this could expand further when these drugs are commercialized

Supply

Supply market is very small at present since there are only four drugs in the market
Currently there are 4-5 major CMOs in the market and they may not be able to support the growing demand, once all drugs lined up for regulatory approval get market authorisation
All oligo API manufacturing CMOs have planned expansion of their existing facility or entered into joint ventures to construct a new manufacturing facility

Demand

Demand is expected to increase many folds in the near future
With more drugs entering the market, there will be increased reliance on CMOs for their manufacturing expertise and experience
Well known CMOs with many years of experience in this space many be more sought after
Due to lack of capacity CMOs who are next in line with a good track record may also be considered

Market Trends – Oligonucleotide API

In November 2017, RiboBio and GE Healthcare entered into a Strategic Partnership to build an Oligonucleotide CRO/CMO facility
ST Pharm announced the construction of its new oligo manufacturing unit in Korea. This plant is said to be operational by 2019
Similarly, GeneDesign a subsidiary of Ajinomoto announced that it will establish a new plant for Oligo API manufacturing in Japan, expected to be operational by 2019
Nitto Denko Avecia in July 2017 expanded their Oligonucleotide API manufacturing facility in Massachusetts by 2000 square feet. The facility is capable of producing oligonucleotide API capacity up to 1.8 molecular weight (mol)
In July 2017, CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create end-to-end solution for oligonucleotide-based drug discovery

Buy Report ( ~~$499~~ $399)

Talk to sales

Download Sample